The Implications of New Research Findings for the Management of Endometrial Cancer

1

Introduction

00:00 • 3min

2

The Rise of Endometrial Cancer

03:04 • 2min

3

The Evolution of the Biomarker Story

05:19 • 2min

4

The Ruby Study and the NRG Study on Endometrial Cancer

06:53 • 4min

5

The Role of PD-1 Inhibitors in the DMMR Population

10:59 • 2min

6

Ruby and GY018: A Comparison of DMMR and COVID

13:26 • 2min

7

The Progression Free Survival of Pembrolizumab

15:47 • 3min

8

The Response Rates of Single Agent IO in MSI High Patients

18:21 • 4min

9

MSI High Patients: A No Brainer?

22:03 • 3min

10

Carbotextile Followed by Linvatinev Pembro for MS Stable Patients

24:52 • 2min

11

How to Add an IO to a Patient With Metastatic MSI High Disease

27:02 • 2min

12

The Future of Anti-Angiogenic Therapy

29:08 • 2min

13

The Importance of Trials in Chemotherapy

30:59 • 5min

14

The Future of DOR-Stahla-Mab and Lendatnib

36:28 • 4min

15

The Role of Trope Two in Breast Cancer

40:55 • 3min

16

The Importance of HER2 in Metastatic Endometrial Cancer

43:30 • 3min

17

How to Treat a Lego Metastatic Disease

46:15 • 2min

18

The Importance of Local Therapies in Lower Risk Metastatic Disease

48:21 • 2min

19

The Difference Between PEMBRO and L and X

50:38 • 2min

20

The Future of Circulating Tumor DNA in Endometrial and Gynecologic Cancer

52:33 • 2min

21

How to Dose Lin-Vatna Pembroe for Endometrial Cancer

54:45 • 2min

22

How to Manage Diarrhea on Lenvatt and Pembro

56:25 • 2min

23

Adjutant Therapy for PPF3 Mutated Tumors

58:02 • 2min

24

The DMMR MSI High and Metastatic Bladder Cancer

59:37 • 2min